Sana Biotechnology Q4 adjusted EPS misses estimates

Reuters03-04

<a href="https://laohu8.com/S/SANA">Sana Biotechnology</a> Q4 adjusted EPS misses estimates

Overview

Biotech firm reported Q4 adjusted EPS miss analyst expectations
Raised $133.7 mln from stock sales, cash runway into late 2026

Outlook

Sana anticipates cash runway into late 2026

Result Drivers

RESEARCH AND DEVELOPMENT EXPENSES: For the three months ended December 31, 2025, research and development expenses, inclusive of non-cash expenses, were $34.9 million

Company press release: ID:nGNX25tq5m

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted EPS	Miss	-$0.16	-$0.13 (7 Analysts)
Q4 EPS		-$0.21
Q4 Operating Expenses		$61.20 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sana Biotechnology Inc is $7.50, about 80.7% above its March 2 closing price of $4.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616374052?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 05:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616374052","market":"nz","top_or_hot":-1,"title":"Sana Biotechnology Q4 adjusted EPS misses estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SANA\">Sana Biotechnology</a> Q4 adjusted EPS misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biotech firm reported Q4 adjusted EPS miss analyst expectations</p></li><li><p>Raised $133.7 mln from stock sales, cash runway into late 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sana anticipates cash runway into late 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>RESEARCH AND DEVELOPMENT EXPENSES: </span>For the three months ended December 31, 2025, research and development expenses, inclusive of non-cash expenses, were $34.9 million</p></li></ul><p>Company press release: <span>ID:nGNX25tq5m</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Miss</p></td><td><p>-$0.16</p></td><td><p>-$0.13 (7 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$61.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Sana Biotechnology Inc is $7.50, about 80.7% above its March 2 closing price of $4.15</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sana Biotechnology Q4 adjusted EPS misses estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSana Biotechnology Q4 adjusted EPS misses estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 05:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SANA\">Sana Biotechnology</a> Q4 adjusted EPS misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biotech firm reported Q4 adjusted EPS miss analyst expectations</p></li><li><p>Raised $133.7 mln from stock sales, cash runway into late 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sana anticipates cash runway into late 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>RESEARCH AND DEVELOPMENT EXPENSES: </span>For the three months ended December 31, 2025, research and development expenses, inclusive of non-cash expenses, were $34.9 million</p></li></ul><p>Company press release: <span>ID:nGNX25tq5m</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Miss</p></td><td><p>-$0.16</p></td><td><p>-$0.13 (7 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$61.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Sana Biotechnology Inc is $7.50, about 80.7% above its March 2 closing price of $4.15</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL1N3ZR19Y:1","article_id":"2616374052","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616374052","pubTimestamp":1772573992,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sana Biotechnology Q4 adjusted EPS misses estimatesOverviewBiotech firm reported Q4 adjusted EPS miss analyst expectationsRaised $133.7 mln from stock sales, cash runway into late 2026OutlookSana anti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SANA":"Sana Biotechnology, Inc."},"translate_title":"Sana Biotechnology第四季度调整后每股收益未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SANA":0.9},"content_text":"Sana Biotechnology Q4 adjusted EPS misses estimatesOverviewBiotech firm reported Q4 adjusted EPS miss analyst expectationsRaised $133.7 mln from stock sales, cash runway into late 2026OutlookSana anticipates cash runway into late 2026Result DriversRESEARCH AND DEVELOPMENT EXPENSES: For the three months ended December 31, 2025, research and development expenses, inclusive of non-cash expenses, were $34.9 millionCompany press release: ID:nGNX25tq5mKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Adjusted EPSMiss-$0.16-$0.13 (7 Analysts)Q4 EPS-$0.21Q4 Operating Expenses$61.20 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Sana Biotechnology Inc is $7.50, about 80.7% above its March 2 closing price of $4.15For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616374052","isCrawlerRequest":true}